170 related articles for article (PubMed ID: 24715451)
1. Musculoskeletal applications of PET/MR.
Lee IS; Jin YH; Hong SH; Yang SO
Semin Musculoskelet Radiol; 2014 Apr; 18(2):203-16. PubMed ID: 24715451
[TBL] [Abstract][Full Text] [Related]
2. Oncologic PET/MRI, part 2: bone tumors, soft-tissue tumors, melanoma, and lymphoma.
Buchbender C; Heusner TA; Lauenstein TC; Bockisch A; Antoch G
J Nucl Med; 2012 Aug; 53(8):1244-52. PubMed ID: 22782313
[TBL] [Abstract][Full Text] [Related]
3. Integrated whole-body PET/MR hybrid imaging: clinical experience.
Quick HH; von Gall C; Zeilinger M; Wiesmüller M; Braun H; Ziegler S; Kuwert T; Uder M; Dörfler A; Kalender WA; Lell M
Invest Radiol; 2013 May; 48(5):280-9. PubMed ID: 23442775
[TBL] [Abstract][Full Text] [Related]
4. Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology.
Schmidt GP; Kramer H; Reiser MF; Glaser C
Top Magn Reson Imaging; 2007 Jun; 18(3):193-202. PubMed ID: 17762383
[TBL] [Abstract][Full Text] [Related]
5. Positron emission tomography/magnetic resonance imaging evaluation of lung cancer: current status and future prospects.
Yoon SH; Goo JM; Lee SM; Park CM; Seo HJ; Cheon GJ
J Thorac Imaging; 2014 Jan; 29(1):4-16. PubMed ID: 24296699
[TBL] [Abstract][Full Text] [Related]
6. [Application of MR/PET in oncologic imaging].
Schwenzer NF; Pfannenberg C; Reischl G; Werner MK; Schmidt H
Rofo; 2012 Sep; 184(9):780-7. PubMed ID: 22618473
[TBL] [Abstract][Full Text] [Related]
7. Hematopoietic tumors and metastases involving bone.
Kim SH; Smith SE; Mulligan ME
Radiol Clin North Am; 2011 Nov; 49(6):1163-83, vi. PubMed ID: 22024293
[TBL] [Abstract][Full Text] [Related]
8. PET/CT, MR, and PET/MR in Lymphoma and Melanoma.
Schwenzer NF; Pfannenberg AC
Semin Nucl Med; 2015 Jul; 45(4):322-31. PubMed ID: 26050659
[TBL] [Abstract][Full Text] [Related]
9. "One-stop-shop" staging: should we prefer FDG-PET/CT or MRI for the detection of bone metastases?
Heusner T; Gölitz P; Hamami M; Eberhardt W; Esser S; Forsting M; Bockisch A; Antoch G
Eur J Radiol; 2011 Jun; 78(3):430-5. PubMed ID: 19945240
[TBL] [Abstract][Full Text] [Related]
10. Fluorine-18-deoxyglucose-positron emission tomography imaging with magnetic resonance and computed tomographic correlation in the evaluation of bone and soft-tissue sarcomas: a pictorial essay.
Tewfik JN; Greene GS
Curr Probl Diagn Radiol; 2008; 37(4):178-88. PubMed ID: 18502325
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors.
Gaertner FC; Beer AJ; Souvatzoglou M; Eiber M; Fürst S; Ziegler SI; Brohl F; Schwaiger M; Scheidhauer K
Invest Radiol; 2013 May; 48(5):263-72. PubMed ID: 23385399
[TBL] [Abstract][Full Text] [Related]
12. F-18 FDG PET/CT staging of multiple myeloma with diffuse osseous and extramedullary lesions.
Wiesenthal AA; Nguyen BD
Clin Nucl Med; 2007 Oct; 32(10):797-801. PubMed ID: 17885362
[TBL] [Abstract][Full Text] [Related]
13. Posttherapy imaging of musculoskeletal neoplasms.
Garner HW; Kransdorf MJ; Peterson JJ
Radiol Clin North Am; 2011 Nov; 49(6):1307-23, vii. PubMed ID: 22024300
[TBL] [Abstract][Full Text] [Related]
14. Bone and soft-tissue sarcoma: preoperative staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging.
Tateishi U; Yamaguchi U; Seki K; Terauchi T; Arai Y; Kim EE
Radiology; 2007 Dec; 245(3):839-47. PubMed ID: 18024454
[TBL] [Abstract][Full Text] [Related]
15. First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses.
Drzezga A; Souvatzoglou M; Eiber M; Beer AJ; Fürst S; Martinez-Möller A; Nekolla SG; Ziegler S; Ganter C; Rummeny EJ; Schwaiger M
J Nucl Med; 2012 Jun; 53(6):845-55. PubMed ID: 22534830
[TBL] [Abstract][Full Text] [Related]
16. Detection of hematogenous bone metastasis in cervical cancer: 18F-fluorodeoxyglucose-positron emission tomography versus computed tomography and magnetic resonance imaging.
Liu FY; Yen TC; Chen MY; Lai CH; Chang TC; Chou HH; Hong JH; Chen YR; Ng KK
Cancer; 2009 Dec; 115(23):5470-80. PubMed ID: 19739235
[TBL] [Abstract][Full Text] [Related]
17. Initial experience of MR/PET in a clinical cancer center.
Partovi S; Robbin MR; Steinbach OC; Kohan A; Rubbert C; Vercher-Conejero JL; Kolthammer JA; Faulhaber P; Paspulati RM; Ros PR
J Magn Reson Imaging; 2014 Apr; 39(4):768-80. PubMed ID: 24006287
[TBL] [Abstract][Full Text] [Related]
18. Discrepancies and priorities in staging and restaging malignant lymphoma by SPET, SPET/CT, PET/CT and PET/MRI.
Chavdarova LI; Tzonevska AD; Piperkova EN
Hell J Nucl Med; 2013; 16(3):223-9. PubMed ID: 24137584
[TBL] [Abstract][Full Text] [Related]
19. Prostate carcinoma: diffusion-weighted imaging as potential alternative to conventional MR and 11C-choline PET/CT for detection of bone metastases.
Luboldt W; Küfer R; Blumstein N; Toussaint TL; Kluge A; Seemann MD; Luboldt HJ
Radiology; 2008 Dec; 249(3):1017-25. PubMed ID: 18849502
[TBL] [Abstract][Full Text] [Related]
20. PET/CT in benign and malignant musculoskeletal tumors and tumor-like conditions.
Choi YY; Kim JY; Yang SO
Semin Musculoskelet Radiol; 2014 Apr; 18(2):133-48. PubMed ID: 24715446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
